The French Competition Authority fines a pharmaceutical laboratory for having first prevented then restricted the development of generic versions of a drug (Janssen-Cilag / Johnson & Johnson)

The Autorité de la concurrence imposes a fine of 25 million euros on Janssen-Cilag laboratory and its parent company Johnson & Johnson for having first prevented then restricted the development of generic versions of Durogesic, its originator medicinal product.* Background Following a referral by the pharmaceutical laboratory Ratiopharm [1], now Teva Santé, the Autorité de la concurrence has today issued a decision imposing a fine of 25 million euros on Janssen-Cilag and its parent company Johnson & Johnson for having delayed the arrival to the market of a generic version of the Durogesic and for then blocking the development of this generic medicinal product. Durogesic is a powerful opioid analgesic, with the active ingredient fentanyl, prescribed for treatment of severe pain.

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

Quotation

French Competition Authority, The French Competition Authority fines a pharmaceutical laboratory for having first prevented then restricted the development of generic versions of a drug (Janssen-Cilag / Johnson & Johnson), 20 December 2017, e-Competitions Bulletin Competition in the Pharmaceutical sector, Art. N° 85529

Visites 283

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues